ClinicalTrials.gg

Program

MTX-463

A development code.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Mediar Therapeutics.

Furthest: phase 2, since Apr 14, 20253 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mediar Therapeutics31 open or runningphase 2since Apr 14, 2025Apr 22, 2024Aug 2027phase 2 · NCT06967805

Also a collaborator on its studies: icon-plc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 22, 2024First study: phase 1 study in HealthyFirst studyNCT06401213 · 56 enrolled · United States
  2. Apr 14, 2025Phase 2 study in Idiopathic Pulmonary FibrosisNCT06967805 · 168 enrolled · United States, Argentina, Australia and more
  3. Feb 10, 2026Phase 1 study in Healthy Adult MaleNCT07450521 · 8 enrolled · United States

Ahead

  1. Aug 2027Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT06967805

TargetBeta

CCN4 →read by rule
“MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1).”study text, by rule · the study

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07450521Healthy Adult Male · United States1CompletedMar 11, 20268
NCT06967805Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more2Active, not recruitingAug 2027168
NCT06401213Healthy · United States1CompletedNov 15, 202456

How it is read

Names in the registry

  • “MTX-463”, 3 entries

Codes read as this program: MTX463.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.